Funded Biotechnology Startups in Menlo Park
The 24 biotechnology companies on this page represent funded rounds in Menlo Park spanning from May 2020 through July 2025.
The 24 biotechnology companies on this page represent funded rounds in Menlo Park spanning from May 2020 through July 2025. The largest disclosed raise belongs to 180 Life Sciences, which closed a $425M round on July 29, 2025 — the most recent entry in the set. Grail's $390M raise from May 2020 and BillionToOne's $130M Series D in June 2024 are the next two largest disclosed transactions.
Round stages span from Seed to Series D: MedaSystems raised a Seed round in March 2025, while Calysta and BillionToOne each reached Series D. Four Series C rounds appear — Synthekine ($100M), DiCE Molecules ($60M), Allay Therapeutics ($60M), and Antheia ($56M). Eight of the 24 entries date from 2024 or 2025, and four companies — MedaSystems, AN2 Therapeutics, Invenio Imaging, and Ionpath — have undisclosed round amounts.
Most recent rounds
24 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these Menlo Park biotech companies?
The three largest are 180 Life Sciences at $425M (July 2025), Grail at $390M (May 2020), and BillionToOne's Series D at $130M (June 2024). Adverum Biotechnologies raised $128M in February 2024, making it the fourth-largest disclosed amount in the set.
Which round stages appear most frequently in this dataset?
"Series Unknown" is the most common classification, covering ten companies including Personalis, Adverum Biotechnologies, Octave, TrueBinding, and Tivic Health. Series C is the next most represented stage, with four companies — Synthekine ($100M), DiCE Molecules ($60M), Allay Therapeutics ($60M), and Antheia ($56M) — raising at that level.
How much of the funding activity shown is from 2024 or 2025?
Eight of the 24 entries date from 2024 or 2025. Three companies — 180 Life Sciences ($425M), Antheia ($56M), and MedaSystems (undisclosed) — closed rounds in the first seven months of 2025 alone, with 180 Life Sciences' July 29, 2025 round being the most recent in the set.
What is the range of disclosed round sizes shown?
The smallest disclosed round is IncellDx at $500K (July 2024), and the largest is 180 Life Sciences at $425M (July 2025). Four companies — MedaSystems, AN2 Therapeutics, Invenio Imaging, and Ionpath — have undisclosed amounts, so the full capital deployment across all 24 entries cannot be calculated from this data alone.
Are there any non-VC financing structures in this dataset?
Ionpath completed a Corporate Round in May 2022 with an undisclosed amount. Alladapt Immunotherapeutics' $119M raise in June 2022 is classified as "Venture - Series Unknown," and two entries — Strateos ($56M, June 2021) and Grail ($390M, May 2020) — have no round type specified.
Which companies in this set raised at the earliest stage?
MedaSystems is the only company with a Seed round, closing an undisclosed amount in March 2025. The next earliest stage entries are Revelation Biosciences' $9M Series A (January 2021) and 3T Biosciences' $40M Series A (August 2022).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.